Merck: adjusted net income close to $4 billion in Q3

(CercleFinance.com) - Merck announces that its sales reached $16.
65 billion in Q3, up 4% (or +7% at constant exchange rates).

Adjusted net income came to $3.98 billion, down 27% (or -23% at constant exchange rates), leaving adjusted EPS of $1.57, down 26% (-23% at constant exchange rates) above expectations, yet including a net charge of $0.79 per share related to certain business development transactions.

Our third-quarter results were solid as we continue to make progress toward 2025 and beyond," said Robert M. Davis, Merck's Chief Executive Officer.

' Our pipeline is advancing and expanding, demonstrating our success in creating a sustainable innovation engine, and positions Merck with a more diversified portfolio to drive growth. I remain convinced of the strength of our business', he added.

Merck is now targeting sales of between $63.6 and $64.1 billion in 2024 with adjusted EPS of between $7.72 and $7.77 including a net negative impact of $0.24 per share related to business development transactions with Curon Biopharmaceutical and Daiichi Sankyo.

Copyright (c) 2024 CercleFinance.com. All rights reserved.